A Rollover Protocol to Allow Continued Access to Tivozanib Hydrochloride (AV-951) for
Subjects Enrolled in Other Tivozanib Hydrochloride Protocols
The main purpose of this study is to allow participants continued access to tivozanib for those who have been previously treated with it as part of a clinical trial for their metastatic renal cell carcinoma or any other type of cancer. Participants must have been on a clinical trail with tivozanib and must have seen clinical benefit from the drug.
Locally advanced or metastatic renal cell carcinoma (mRCC).
Open only to participants who have previously been treated with tivozanib as part of a clinical study and who have seen a a clinical benefit while tolerating the drug.
18 - 100
Healthy Volunteers Needed
Duration of Participation
As long as clinical benefit is being seen.
AVEO Pharmaceuticals, Inc.